About Us

Leadership

  • Adam R. Craig, M.D., Ph.D.

    President and Chief Executive Officer

    Dr. Craig was appointed to serve as one of our directors and as our President and Chief Executive Officer in March 2017. Dr. Craig has worked as an independent consultant providing strategic and operational advice and support to CTI BioPharma and other hematology/oncology biotechnology companies since 2016. Prior to consulting, Dr. Craig was Chief Medical Officer (CMO) and Executive Vice President of Development of Sunesis Pharmaceuticals from 2012 to 2016. From 2008 to 2012, Dr Craig was CMO and Senior Vice President of Chemgenex Pharmaceuticals Ltd, a publicly traded biotechnology company which was acquired by Cephalon/Teva Pharmaceuticals in 2011. Dr. Craig is a Member of the Royal College of Physicians (UK) and undertook Post-Graduate Training in Pediatrics and Pediatric Oncology. Dr. Craig earned his Bachelor’s and Medical degrees from Charing Cross and Westminster Medical School, University of London, and holds a Ph.D. in Molecular Oncology from Leeds University in the U.K. and an MBA from the Open Business School, in the United Kingdom. Dr. Craig recently served as a Product Development Reviewer for the Cancer Prevention Research Institute of Texas.

  • Jack W. Singer, M.D.

    EVP, Chief Scientific Officer, Interim Chief Medical Officer and Global Head of Translational Medicine

     

    Jack W. Singer, M.D., is a founder of CTI BioPharma and currently serves as the Company’s Executive Vice President, Chief Scientific Officer, Interim Chief Medical Officer and Global Head of Translational Medicine. Dr. Singer has been one of the Company’s directors since its inception in September 1991. From 2004 to June 2012, Dr. Singer was the Company’s Chief Medical Officer. From July 1995 to January 2004, Dr. Singer was Executive Vice President, Research Program Chairman, and from April 1992 to July 1995, he served as Executive Vice President, Research and Development. He also serves on the board of directors of DiaKine Therapeutics Inc.

    Prior to joining CTI, Dr. Singer was Professor of Medicine at the University of Washington and full Member of the Fred Hutchinson Cancer Research Center. From 1975 to 1992, he was the Chief of Medical Oncology at the Veterans Administration Medical Center in Seattle. Dr. Singer received his M.D. from State University of New York, Downstate Medical College.

  • Bruce J. Seeley

    EVP, Chief Commercial and Administrative Officer and Secretary

    Bruce J. Seeley joined CTI BioPharma in July 2015 as Executive Vice President, Chief Commercial and Administrative Officer and Secretary. Mr. Seeley leads CTI BioPharma’s commercial organization worldwide, including sales, marketing, commercial operations, medical affairs and supply chain.

    Mr. Seeley has more than 25 years of global commercial experience and a proven track record of successfully launching products in various markets and regulatory environments. Most recently, Mr. Seeley was Senior Vice President and General Manager of Diagnostics at NanoString Technologies Inc. overseeing the launch of the diagnostic product PROSIGNA® for early stage breast cancer. Previously, he was Executive Vice President of Commercial at Seattle Genetics where he built and led the commercial organization, including marketing, sales and managed markets, and successfully launched the company’s first product, ADCETRIS®, a targeted therapy for lymphoma. He also previously held key leadership positions in marketing at Genentech (now a member of the Roche Group), where he led the launch of HERCEPTIN® in adjuvant breast cancer. Earlier in his career he held various commercial roles at Aventis Pharmaceuticals Inc. (a part of Sanofi) and Bristol-Myers Squibb Co. Mr. Seeley received a B.A. In Sociology from the University of California at Los Angeles.

  • Matthew J. Plunkett, Ph.D.

    EVP, Chief Business Officer

    Matthew J. Plunkett, Ph.D., was named Executive Vice President, Chief Business Officer, in December 2015. He joined CTI BioPharma in September 2012 as Executive Vice President, Corporate Development. Dr. Plunkett leads CTI BioPharma’s partnering strategy including development collaborations, licensing agreements, and strategic alliances. He is also responsible for manufacturing, investor relations, program management, and alliance management within the company.

    Dr. Plunkett has more than 15 years’ experience in the biopharmaceutical industry, spanning basic research, investment banking, and executive operational roles. Most recently, Dr. Plunkett was Chief Financial Officer at the California Institute for Regenerative Medicine, a $3 billion fund for California stem cell research. Previously, he was Vice President and Chief Financial Officer at iPierian, a privately held development-stage biotechnology company. He also spent nine years at Oppenheimer & Co. and its U.S. predecessor, CIBC World Markets, most recently serving as Managing Director and head of West Coast Biotechnology. He has advised on more than 70 completed transactions for companies in the U.S., Europe and Australia, including more than $4 billion in equity and equity-linked transactions and $1 billion in merger, acquisition and other financial advisory transactions. He began his scientific career at Sunesis Pharmaceuticals and Axys Advanced Technologies.

    Dr. Plunkett received a Ph.D. in Organic Chemistry from the University of California, Berkeley, and a B.S. in Chemistry from Harvey Mudd College, Claremont, California.

You Are Leaving CTI BioPharma

You have selected a link to a third-party website. This link is provided solely as a convenience to you and not as an endorsement by CTI BioPharma of such third-party website. CTI BioPharma is not responsible for and does not make any representations regarding the accuracy of materials on such third-party site.

Continue to the Requested Site
Return to CTI BioPharma

Hello! We are pleased to announce that Cell Therapeutics has changed its name to

Enter Site